About this trial
The goal of this clinical trial is to determine the best combination of drugs and drug delivery routes to treat surgically naive chronic rhinitis patients. The main question it aims to answer is:
Do high volume, high pressure delivery mechanisms in nasal irrigation improve the efficacy of azelastine combined with nasal steroid mometasone as compared to the standard low pressure, low volume delivery mechanisms in nasal sprays?
Subjects will complete six months of one of three medication regimens:
1. Saline irrigation followed by azelastine spray and mometasone spray 2. Mometasone saline irrigation 3. Azelastine saline irrigation combined with mometasone saline irrigation.
Eligibility criteria
Qualifiers
Adults 18 years and older seeking treatment for chronic rhinitis and willing to undergo six months of topical therapy.
Diagnosis of Chronic Rhinitis.
Disqualifiers
The patient has diagnosis(es) other than chronic rhinitis that can account for his/her symptoms (septal deviation, nasal valve collapse, chronic sinusitis).
Use of oral antihistamines or oral steroids, unless patient undergoes a 4 week washout period.
Smokers (tobacco, marijuana, vaping, etc.).
Known or suspected pregnancy, or lactation.
Trial design
Treatments tested in this trial
- Azelastine (137 mcg/spray) Nasal Spray and Mometasone (50 mcg/spray) Nasal Spray
- Mometasone Nasal Irrigation (1 mg capsule)
- Mometasone (1 mg) and Azelastine (1 mg) Nasal Irrigation